Hormonal replacement therapy for aging men? The debate goes on

European Urology

Volumn 46, Issue 2, 2004, Pages 155-161

  Hargreave, T B ^a   Meuleman, E J H ^b   Weidner, W ^c  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

ADAM; Androgens; HRT for men; Male aging; PADAM

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; CONTRACEPTIVE AGENT; DUTASTERIDE; ESTRADIOL; FINASTERIDE; FLUOXYMESTEROLONE; INSULIN; METHYLTESTOSTERONE; PRASTERONE; SEX HORMONE BINDING GLOBULIN; STEROID; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TESTOSTERONE CIPIONATE; TESTOSTERONE ENANTATE; TESTOSTERONE PROPIONATE; TESTOSTERONE UNDECANOATE; TRESTOLONE; UNCLASSIFIED DRUG;

AGING; DISEASE EXACERBATION; DRUG SAFETY; DRUG USE; GEL; HORMONE DEFICIENCY; HORMONE SUBSTITUTION; HUMAN; HYDROXYLATION; LIVER TOXICITY; NONHUMAN; PARTIAL ANDROGEN DECLINE IN THE AGING MALE SYNDROME; POLYCYTHEMIA; PRIORITY JOURNAL; PROSTATE; PROSTATE CANCER; PROTEIN BLOOD LEVEL; QUESTIONNAIRE; REVIEW; SCREENING; SIDE EFFECT; SYMPTOMATOLOGY; SYNDROME;

ANDROGENS; HORMONE REPLACEMENT THERAPY; HUMANS; MALE; TESTOSTERONE;

EID: 3142536738     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2004.04.003     Document Type: Review

References (61)

1. Vermeulen A., Kaufman J.M., Giagulli V.A. Influence of some biological indexes on sex hormone-binding globulin and androgen levels in aging or obese males. J. Clin. Endocrinol. Metab. 81(5):1996;1821-1826
2. Feldman H.A., Longcope Ch., Derby C.A., Johannes C.B., Araujo A.B., Coviello A.D., et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts Male Aging Study. J. Clin. Endocrinol. Metabol. 87:2002;589-598
3. Lunenfeld B. Aging male. Aging Male. 1:1998;1-7
4. Morales A., Lunenfeld B. Investigation, treatment and monitoring of late-onset hypogonadism in males. Official recommendations of ISSAM. Aging Male. 5:2002;74-86
5. Blanker M.H., Driessen L.F.C., Bosch J.L.H.R., Bohnen A.M., Thomas S., Prins A., et al. Health status and its correlates among Dutch community-dwelling older men with and without lower urogenital tract dysfunction. Eur. Urol. 41:2002;602-607
6. Beutel M.E., Wiltink J., Schwarz R., Weidner W., Brähler E. Complaints of the aging male based on a representative community study. Eur. Urol. 41:2002;85-93
7. Tan R.S., Philip P.S. Perceptions of and risk for andropause. Arch. Androl. 43:1999;97-103
8. Feldman H.A., Goldstein I., Hatzichristou D.G., Krane R.J., McKinley J.B. Results of the Massachusetts Male Aging Study. J. Urol. 151:1994;54-61
9. Meuleman E.J., Donkers L.H., Robertson C., Keech M., Boyle P., Kiemeney L.A. Erectile dysfunction: prevalence and effect on the quality of life; Boxmeer study. Ned. Tijdschr. Geneeskd. 145(12):2001;576-581
10. Johannes CB, Araujo AG, Feldman HA, Derby CA, Kleinman KP, McKinley JB. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol 2000;163:460-3.
11. Schiavi R.C., Schreiner-Engel P., Mandeli J., Schanzer H., Lohen E. Healthy aging and male sexual function. Am. J. Psychiatry. 147:1990;766-771
12. Perry P.J., Lund B.J., Amdt S., et al. Biovailable testosterone as a correlate of cognition, psychological status, quality of life, and sexual function in aging males: implications for testosterone replacement therapy. Ann. Clin. Psychiatry. 13:2001;75-80
13. Kaufman J.M., Sjoen G.T. The effects of testosterone deficiency on male sexual function. Aging Male. 5:2002;242-247
14. Nieschlag E. The endocrine function of human testis in regard to sexuality. In: Ciba Foundation Symposium: Sex, hormones and Behaviour. Amsterdam: Excerpta Medica; 1979. p. 182-208.
15. Gooren L.J.G. Androgen levels and sex functions in testosterone-treated hypogonadal men. Arch Sex Behav. 16:1987;463-473
16. Bagatell C.J., Heiman J.R., Matsumoto A.M., Rivier J.E., Bremner W.J. Metabolic and behavioural effects of high-dose exogeneous testosterone in healthy men. J. Clin. Endocrinology Metabol. 79:1994;561-567
17. Bancroft J. Hormones and human sexual behaviour. J. Sex Marital Ther. 10:1984;3-21
18. Park K.H., Kim S.W., Kim K.D., Paick J.S. Effects of androgens on the expression of nitric oxide synthase mRNAs in rat corpus cavernosum. BJU Int. 83(3):1999;327-333
19. Baba K., Yajima M., Carrier S., Morgan D.M., Nunes L., Lue T.F., et al. Delayed testosterone replacement restores nitric oxide synthase-containing nerve fibres and the erectile response in rat penis. BJU Int. 85(7):2000;953-958
20. Reilly C.M., Zamorano P., Stopper V.S., Mills T.M. Androgenic regulation of NO availability in rat penile erection. J. Androl. 18(2):1997;110-115. Comment in: J Androl. 1997;18(6):745
21. Zvara P., Sioufi R., Schipper H.M., Begin L.R., Brock G.B. Nitric oxide mediated erectile activity is a testosterone dependent event: a rat erection model. Int. J. Impot. Res. 7(4):1995;209-219
22. Marin R., Escrig A., Abreu P., Mas M. Androgen-dependent nitric oxide release in rat penis correlates with levels of constitutive nitric oxide synthase isoenzymes. Biol. Reprod. 61(4):1999;1012-1016
23. Wu X.H., Hu L.Q. Effect of androgen on penile erection induced by L-arginine in paraventricular nucleus. Zhonghua Nan Ke Xue. 8(4):2002;270-272
24. Reilly C.M., Lewis R.W., Stopper V.S., Mills T.M. Androgenic maintenance of the rat erectile response via a non-nitric-oxide-dependent pathway. J. Androl. 18(6):1997;588-594
25. Kalinchenko S.Y., Kozlov G.I., Gontcharov N.P., Katsiya G.V. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male. 6(2):2003;94-99
26. Aversa A., Isidori A.M., Spera G., Lenzi A., Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin. Endocrinol. (Oxf). 58(5):2003;632-638
27. Morales A. Editorial comment. Eur. Urol. 41:2003;92-93
28. Morley J.E., Charlton E., Patrick P., Kaiser F.E., Cadeau P., McCready D., et al. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 49:2000;1239-1242
29. Heinemann L.A.J., Zimmermann T., Vermeulen A., Thiel C. A new "aging male's symptoms" (AMS) rating scale. Aging Male. 2:1999;105-114
30. Heinemann L.A.J., Saad F., Thiele K., Wood-Dauphinee S. The aging males' symptoms rating scale: cultural and linguistic validation into English. Aging Male. 4:2002;14-22
31. Smith K.W., Feldmann H.A., McKinlay J.B. Construction and field validation of a self-administerial screener for testosterone deficiency in aging men. Clin. Endocrinol. 53:2000;703-711
32. Heinemann L.A., Thiel C., Assmann A., Zimmermann T., Hummel W., Vermeulen A. Sex differences in "climateric symptoms" with increasing age? A hypothesis-generating analysis of cross-sectional population surveys. Aging Male. 3:2000;124-131
33. Schatzl G., Madersbacher S., Temml C., Krenn-Schinkel K., Nader A., Sregi G., et al. Serum androgen levels in men: impact of health status and age. Urology. 61(3):2003;629-633
34. Tenover J.S., Matsumoto A.M., Clifton D.K., Bremner W.J. Age-related alterations in the circadian rhythms of pulsatile luteinizing hormone and testosterone secretion in healthy men. J Gerontol. 43(6):1988;M163-M169
35. Plymate S.R., Tenover J.S., Bremner W.J. Circadian variation in testosterone, sex hormone binding globulin, and calculated non-sex hormone-binding globulin bound testosterone in healthy young and elderly men. J. Androl. 10:1989;366-371
36. Buchanan G., Yang M., Harris J.M., Nahm H.S., Han G., Moore N., et al. Mutations at the boundary of the hinge and ligand binding domain of the androgen receptor confer increased transactivation function. Mol. Endocrinol. 15(1):2001;46-56
37. Wang Q., Lu J., Yong E.L. Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region. J. Biol. Chem. 276(10):2001;7493-7499
38. Giovannucci E., Stampfer M.J., Krithivas K., Brown M., Dahl D., Brufsky A., et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proc. Natl. Acad. Sci. USA. 94(7):1997;3320-3323
39. Krithivas K., Yurgalevitch S.M., Mohr B.A., Wilcox C.J., Batter S.J., Brown M., et al. Evidence that the CAG repeat in the androgen receptor gene is associated with the age-related decline in serum androgen levels in men. J. Endocrinol. 162(1):1999;137-142
40. Zitzmann M., Depenbusch M., Gromoll J., Nieschlag E. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J. Clin. Endocrinol. Metab. 88(5):2003;2049-2054
41. Bruchovsky N., Wilson J.F. The conversion of testosterone to 5α androstan -17β-ol-3-1 by rat prostate in vivo and in vitro. J. Biol. Chem. 243:1968;2012-2021
42. Partin A.W., Oesterling J.E., Epstein J.I. Influence of age and endocrine factors on the volume of bening prostate hyperplasia. J. Urol. 145:1991;405-409
43. Lowe F.C., McConnell J.D., Hudson P.B., Romas N.A., Boake R., Lieber M., Elhilali M., Geller J., Imperto-McGinely J., Andriole G.L., Bruskewitz R.C., Walsh P.C., Bartsch G., Nacey J.N., Shah S., Pappas F., Ko A., Cook T., Stoner E., Waldstreicher J. Finasteride Study Group Long-term 6-year experience with finasteride in patients with benign prostatic hyperplasia. Urology. 61(4):2003;791-796
44. Morgentaler A., Bruning C.O., DeWolf W.C., Bruning C.O. 3rd Occult prostate cancer in men with low serum testosterone levels. JAMA. 276(23):1996;1904-1906
45. Schleyer-Saunders E. Results of hormone implants in the treatment of the climacteric. J. Am. Geriatr. Soc. 19:1971;114-121
46. Tenover J.S. Effects of testosterone supplementation in the aging male. J. Clin. Endocrinol. Metab. 75:1992;1092-1098
47. De Lignieres B. Transdermal dihydrotestosterone treatment of andropause. Ann. Med. 25:1993;235-241
48. Arver S., Dobs A.S., Meikle A.W., Caramelli K.E., Rajaram L., Sanders S.W., et al. Long-term efficacy and safety of a permeation-enhanced testosterone transdermal system in hypogonadal men. Clin. Endocrinol. (Oxf). 47(6):1997;727-737
49. Hajjar R.R., Kaiser F.E., Morley J.E. Outcomes of long-term testosterone replacement in older hypogonadal males: a retrospective analysis. J. Clin. Endocrinol. Metab. 82(11):1997;3793-3796
50. Behre H.M., Kliesch S., Leifke E., Link T.M., Nieschlag E. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J. Clin. Endocrinol. Metab. 82(8):1997;2386-2390
51. Sih R., Morley J.E., Kaiser F.E., Perry H.M., Patrick P., Ross C., et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J. Clin. Endocrinol. Metab. 82(6):1997;1661-1667
52. Meikle A.W., Arver S., Dobs A.S., Adolfsson J., Sanders S.W., Middleton R.G., et al. Prostate size in hypogonadal men treated with a nonscrotal permeation- enhanced testosterone transdermal system. Urology. 49(2):1997;191-196
53. Morales A.J., Haubrich R.H., Hwang J.Y., Asakura H., Yen S.S. The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clin. Endocrinol. (Oxf). 49(4):1998;421-432
54. Snyder P.J., Peachey H., Hannoush P., Berlin J.A., Loh L., Lenrow D.A., et al. Effect of testosterone treatment on body composition and muscle strength in men over 65 yr of age. J. Clin. Endocrinol. Metab. 84:1999;2647-2653
55. Swerdloff R.S., Wang C., Cunningham G., Dobs A., Iranmanesh A., Matsumotos A.M., et al. Long term pharmacokinetics of transdermal testosterone gel in hypogonadal men. J. Clin. Endocrinol. Metab. 85:2000;4500-4510
56. Gomaa A., Eissa M., El-Gebaley A. The effect of topically applied vasoactive agents and testosterone versus testosterone in the treatment of erectile dysfunction in aged men with low sexual interest. Int. J. Impot. Res. 13:2001;93-99l
57. Jin B., Conway A.J., Handelsman D.J. Effects of androgen deficiency and replacement on prostate zonal volumes. Clin. Endocrinol. (Oxf). 54(4):2001;437-445
58. Cherrier M.M., Asthana S., Plymate S., Baker L., Matsumoto A.M., Peskind E., et al. Testosterone supplementation improves spatial and verbal memory in healthy older men. Neurology. 57(1):2001;80-88
59. Raivio T, Tapanainen JS, Kunelius, Janne OA. Serum androgen bioactivity during 5 alphadihydrotestosterone treatment in elderly men, J Androl 2002;23:919-21.
60. Hong J.H., Ahn T.Y. Oral Testosterone replacement in Korean patient with PADAM0. Aging Male. 5:2002;52-56
61. Pechersky A.V., Mazurov V.I., Semiglazov V.F., Karpischenko A.I., Mikhailichenko V.V., Udintsev A.V. Androgen administration in middle-aged and aging men: effects of oral testosterone undecanoate on dihydrotestosterone, oestradiol and prostate volume. Int. J. Androl. 25(2):2002;119-125